No Data
No Data
Catalyst Watch: Nvidia Event Could Revive Animal Spirits, Fed Meeting, and Nike Earnings
Kairos Pharma Presents Preclinical Data on KROS 101, KROS 401
Kairos Pharma Is Maintained at Buy by D. Boral Capital
Kairos Pharma Price Target Maintained With a $9.00/Share by D. Boral Capital
Kairos Pharma Secures Funding From Department of Defense to Advance Cancer Drug Research | NYSE-A:KAPA
Kairos Pharma Announces New DoD Funding for ENV205 Research